BioAtla, Inc. (NASDAQ:BCAB) Short Interest Down 13.4% in January

BioAtla, Inc. (NASDAQ:BCAB) saw a significant drop in short interest in the month of January. As of January 31st, there was short interest totalling 4,380,000 shares, a drop of 13.4% from the January 15th total of 5,060,000 shares. Based on an average daily volume of 1,110,000 shares, the short-interest ratio is presently 3.9 days.

Analysts Set New Price Targets

Separately, HC Wainwright lowered shares of BioAtla from a “buy” rating to a “neutral” rating in a report on Wednesday, November 13th.

Institutional Investors Weigh In On BioAtla

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Boxer Capital Management LLC acquired a new stake in BioAtla in the 4th quarter valued at $406,000. Jane Street Group LLC increased its stake in BioAtla by 204.1% in the 4th quarter. Jane Street Group LLC now owns 149,291 shares of the company’s stock valued at $88,000 after buying an additional 100,204 shares during the last quarter. Renaissance Technologies LLC increased its stake in BioAtla by 62.2% in the 4th quarter. Renaissance Technologies LLC now owns 829,596 shares of the company’s stock valued at $490,000 after buying an additional 318,196 shares during the last quarter. Highbridge Capital Management LLC acquired a new stake in BioAtla in the 4th quarter valued at $1,484,000. Finally, Norges Bank acquired a new stake in BioAtla in the 4th quarter valued at $230,000. 77.23% of the stock is currently owned by institutional investors and hedge funds.

BioAtla Stock Up 6.6 %

BCAB stock traded up $0.03 during midday trading on Friday, hitting $0.46. The company’s stock had a trading volume of 1,711,107 shares, compared to its average volume of 665,159. BioAtla has a twelve month low of $0.38 and a twelve month high of $4.02. The company’s fifty day moving average price is $0.68 and its 200 day moving average price is $1.41.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.